Literature DB >> 35750263

Characteristics of statewide prescription drug monitoring programs and potentially inappropriate opioid prescribing to patients with non-cancer chronic pain: A machine learning application.

Hsien-Chang Lin1, Zhi Wang2, Yi-Han Hu2, Kosali Simon3, Anne Buu4.   

Abstract

Unnecessary/unsafe opioid prescribing has become a major public health concern in the U.S. Statewide prescription drug monitoring programs (PDMPs) with varying characteristics have been implemented to improve safe prescribing practice. Yet, no studies have comprehensively evaluated the effectiveness of PDMP characteristics in reducing opioid-related potentially inappropriate prescribing (PIP) practices. The objective of the study is to apply machine learning methods to evaluate PDMP effectiveness by examining how different PDMP characteristics are associated with opioid-related PIPs for non-cancer chronic pain (NCCP) treatment. This was a retrospective observational study that included 802,926 adult patients who were diagnosed NCCP, obtained opioid prescriptions, and were continuously enrolled in plans of a major U.S. insurer for over a year. Four outcomes of opioid-related PIP practices, including dosage ≥50 MME/day and ≥90 MME/day, days supply ≥7 days, and benzodiazepine-opioid co-prescription were examined. Machine learning models were applied, including logistic regression, least absolute shrinkage and selection operation regression, classification and regression trees, random forests, and gradient boost modeling (GBM). The SHapley Additive exPlanations (SHAP) method was applied to interpret model results. The results show that among 1,886,146 NCCP opioid-related claims, 22.8% had an opioid dosage ≥50 MME/day and 8.9% ≥90 MME/day, 70.3% had days supply ≥7 days, and 10.3% were when benzodiazepine was filled ≤7 days ago. GBM had superior model performance. We identified the most salient PDMP characteristics that predict opioid-related PIPs (e.g., broader access to patient prescription history, monitoring Schedule IV controlled substances), which could be informative to the states considering the redesign of PDMPs.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Machine learning; Prescribing; Prescription drug monitoring programs; Prescription opioid

Mesh:

Substances:

Year:  2022        PMID: 35750263      PMCID: PMC9307080          DOI: 10.1016/j.ypmed.2022.107116

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.637


  35 in total

1.  Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010.

Authors:  Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

Review 2.  Windmills and pill mills: can PDMPs tilt the prescription drug epidemic?

Authors:  Hallam Gugelmann; Jeanmarie Perrone; Lewis Nelson
Journal:  J Med Toxicol       Date:  2012-12

3.  Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program.

Authors:  Chris Delcher; Alexander C Wagenaar; Bruce A Goldberger; Robert L Cook; Mildred M Maldonado-Molina
Journal:  Drug Alcohol Depend       Date:  2015-02-19       Impact factor: 4.492

4.  Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.

Authors:  Hsien-Chang Lin; Zhi Wang; Linda Simoni-Wastila; Carol Boyd; Anne Buu
Journal:  Prev Med       Date:  2018-10-11       Impact factor: 4.018

5.  Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines.

Authors:  Christopher M Jones; Jana K McAninch
Journal:  Am J Prev Med       Date:  2015-07-03       Impact factor: 5.043

6.  Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.

Authors:  Thomas R Radomski; Felicia R Bixler; Susan L Zickmund; KatieLynn M Roman; Carolyn T Thorpe; Jennifer A Hale; Florentina E Sileanu; Leslie R M Hausmann; Joshua M Thorpe; Katie J Suda; Kevin T Stroupe; Adam J Gordon; Chester B Good; Michael J Fine; Walid F Gellad
Journal:  J Gen Intern Med       Date:  2018-03-08       Impact factor: 5.128

7.  Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.

Authors:  Hsien-Chang Lin; Zhi Wang; Carol Boyd; Linda Simoni-Wastila; Anne Buu
Journal:  Addict Behav       Date:  2017-09-05       Impact factor: 3.913

8.  Prescription opioid laws and opioid dispensing in U.S. counties: Identifying salient law provisions with machine learning.

Authors:  Silvia S Martins; Emilie Bruzelius; Jeanette A Stingone; Katherine Wheeler-Martin; Hanane Akbarnejad; Christine M Mauro; Megan E Marziali; Hillary Samples; Stephen Crystal; Corey S Davis; Kara E Rudolph; Katherine M Keyes; Deborah S Hasin; Magdalena Cerdá
Journal:  Epidemiology       Date:  2021-07-19       Impact factor: 4.822

9.  The Opioid Epidemic During the COVID-19 Pandemic.

Authors:  Danielle F Haley; Richard Saitz
Journal:  JAMA       Date:  2020-10-27       Impact factor: 157.335

10.  The growing problem of co-treatment with opioids and benzodiazepines.

Authors:  Pinar Karaca-Mandic; Ellen Meara; Nancy E Morden
Journal:  BMJ       Date:  2017-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.